Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3020 |
|
| Actual shortage: | 234 (8%) | |
| Anticipated shortage: | 20 (1%) | |
| Avoided shortage: | 9 (0%) | |
| Resolved: | 2757 (91%) | |
Discontinuation Reports |
356 |
|
| To be discontinued: | 22 (6%) | |
| Discontinued: | 334 (94%) | |
| Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
28 (10%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-RISPERIDONE | 0.50MG | TABLET | Resolved | 2023-07-13 | 2023-08-04 | 198486 |
| APO-RISPERIDONE | 1.0MG | TABLET | Resolved | 2023-07-13 | 2023-08-04 | 198489 |
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2023-09-22 | 2023-12-01 | 205002 |
| APO-RISPERIDONE | 0.50MG | TABLET | Resolved | 2023-11-10 | 2024-04-26 | 209957 |
| APO-RISPERIDONE | 2.0MG | TABLET | Actual shortage | 2023-12-22 | 2024-04-26 | 214247 |
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2024-03-01 | 2024-04-26 | 221090 |
| APO-RISPERIDONE | 1.0MG | TABLET | Actual shortage | 2024-03-27 | 2024-03-27 | 223543 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2017-03-11 | 2017-05-18 | 487 |
| APO-RIVASTIGMINE | 6MG | CAPSULE | Resolved | 2017-07-26 | 2018-03-27 | 17322 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2017-09-04 | 2019-10-15 | 20900 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2018-01-22 | 2018-01-22 | 36947 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2018-01-22 | 2018-03-27 | 36949 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2019-06-05 | 2019-10-07 | 85610 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2019-06-12 | 2019-10-07 | 86336 |
| APO-RIVASTIGMINE | 6MG | CAPSULE | Resolved | 2019-07-03 | 2019-10-07 | 88360 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2021-07-05 | 2021-12-03 | 141854 |
| APO-RIVASTIGMINE | 6MG | CAPSULE | Resolved | 2021-12-03 | 2021-12-13 | 150440 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2022-11-27 | 2023-03-09 | 175898 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2023-07-21 | 2024-01-05 | 199518 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2023-09-28 | 2024-01-05 | 205501 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO DIMENHYDRINATE TAB 50MG | 50MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60435 |
| APO DIMENHYDRINATE TAB 50MG | 50MG | TABLET | Discontinued | 2019-01-02 | 2019-01-02 | 70787 |
| APO-FUROSEMIDE | 20MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60506 |
| APO-FUROSEMIDE | 40MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60509 |
| APO-FUROSEMIDE | 80MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4719 |
| APO GLYBURIDE TAB 2.5MG | 2.5MG | TABLET | Discontinued | 2018-09-07 | 2019-07-04 | 60515 |
| APO GLYBURIDE TAB 5MG | 5MG | TABLET | Discontinued | 2018-09-07 | 2018-12-14 | 60518 |
| APO-HYDROCHLOROTHIAZIDE | Discontinued | 2019-11-26 | 2019-11-26 | 99653 | ||
| APO-HYDROCHLOROTHIAZIDE | 50MG | TABLET | Discontinued | 2018-09-07 | 2019-02-13 | 60521 |
| APO-IBUPROFEN | 300MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60527 |
| APO-IBUPROFEN | 300MG | TABLET | Discontinued | 2019-01-02 | 2019-01-02 | 70793 |
| APO-IBUPROFEN | 400MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60530 |
| APO-IBUPROFEN | 400MG | TABLET | Discontinued | 2019-01-02 | 2019-01-02 | 70799 |
| APO-METOPROLOL (TYPE L) | 50MG | TABLET | Discontinued | 2018-09-07 | 2019-02-02 | 60634 |
| APO-METOPROLOL | 50MG | TABLET | Discontinued | 2018-09-07 | 2019-01-09 | 60631 |
| APO NAPROXEN TAB 125MG | 125MG | TABLET | Discontinued | 2018-09-08 | 2019-08-08 | 60663 |
| APO-NAPROXEN | 250MG | TABLET | Discontinued | 2017-03-30 | 2018-02-05 | 4734 |
| APO-OXAZEPAM | 10MG | TABLET | Discontinued | 2018-09-08 | 2019-08-30 | 60675 |
| APO-OXAZEPAM | 15MG | TABLET | To be discontinued | 2018-09-08 | 2018-09-08 | 60678 |
| APO-OXAZEPAM | 30MG | TABLET | Discontinued | 2018-09-08 | 2019-06-12 | 60681 |